1)Perry AC:Advances in enucleation. Ophthalmol Clin North Am 4:173-182, 1991
2)Lee V, Subak-Sharpe I, Hungerford JL et al:Exposure of primary orbital implantations in postenucleation retinoblastoma patients. Ophthalmology 108:639-640, 2001
3)Custer PL, Trinkaus KM:Porous implant exposure:incidence, management, and motility. Ophthal Plast Reconstr Surg 23:1-7, 2007
4)Kim NJ, Choung HK, Khwang SI et al:Free orbital fat graft to prevent porous polyethylene orbital implant exposure in patients with retinoblastoma. Ophthal Plast Reconstr Surg 21:253-258, 2005
5)Van Acker E, De Potter P:Porous polyethylene(Medpor)orbital implant. Prospective study of 75 primary implantations. J Fr ophtalmol almol 24:1067-1073, 2001
義眼台の使用経験.眼紀 53:883-886,2002
7)Shields JA, Shields CL:Enucleation implants:standard and coated hydroxyapatite implants. In:Shields JA, Shields CL(eds):Intraocular Tumors. An Atlas and Textbook. 2nd ed. 550, Lippincott Williams & Wilkins, Philadelphia, 2008
8)Custer PL, Trinkaus KM, Fornoff J:Comparative motility of hydroxyapatite and alloplastic enucleation implants. Ophthalmology 106:513-516, 1999
9)Lin C-L, Liao S-L, Kao SCS et al:Complications of motility peg placement for porous hydroxyapatite orbital implants. Br J Ophthalmol 86:394-396, 2002